Variables | All patients | Patients with AOD | Patients without AOD | P |
---|---|---|---|---|
n (%) | 159 | 79 (49.6%) | 80 (50.4%) | |
Age (years) | 52.02 ± 12.1 | 54.71 ± 12.0 | 49.36 ± 11.5 | 0.005* |
Gender | 0.115 | |||
Female, n (%) | 113 (71.1) | 61 (77.2) | 52 (65) | |
Male, n (%) | 46 (28.9) | 18 (22.8) | 28 (35) | |
BMI (kg/m2) | 29.55 ± 4.7 | 30.04 ± 4.7 | 29.05 ± 4.6 | 0.195 |
Duration of HT (years) | 3.74 (4) | 5 (3) | 2.5 (4) | 0.037* |
Antihypertensive drugs | ||||
Class (n,%) | ||||
RAS blocker | 86 (54.1) | 45 (57.0) | 41 (51.2) | 0.470 |
Beta blocker | 28 (17.6) | 17 (21.5) | 11 (13.8) | 0.198 |
CCB | 63 (39.6) | 35 (44.3) | 28 (35.0) | 0.230 |
Diuretic | 54 (34) | 26 (33.8) | 28 (36.8) | 0.691 |
CIMT (mm) | 0.75 ± 0.17 | 0.80 ± 0.2 | 0.68 ± 0.1 | 0.001* |
LVMI (g/m2) | 90.05 ± 21.1 | 100.57 ± 21.1 | 78.64 ± 13.9 | 0.001* |
Microalbuminuria (mg/d) | 10 (15,8) | 19.32 (41,7) | 7.17 (6,9) | 0.001* |
Proteinuria (mg/d) | 94.98 (70.4) | 111.25 (114.8) | 84.25 (59.1) | 0.001* |
Retinopathy (n,%) | 0.002* | |||
None | 91 (57.2) | 39 (49.4) | 52 (65.0) | |
Grade I | 28 (17.6) | 13 (16.5) | 15 (24.6) | |
Grade II | 28 (17.6) | 15 (19.0) | 13 (21.3) | |
Grade III | 12 (7.5) | 12 (15.2) | - | |
sTWEAK (pg/mL) | 961.12 (560.9) | 858.4 (365.2) | 1151.58 (598.4) | 0.001* |
IL-17A (pg/mL) | 2.1 (0,9) | 2.34 (0,9) | 1.80 (0,7) | 0.001* |
24-h SBP (mmHg) | 124.31 ± 14.7 | 129.53 ± 16.8 | 119.16 ± 9.9 | 0.001* |
24-h DBP (mmHg) | 77.83 ± 9.8 | 79.53 ± 11.8 | 76.15 ± 6.9 | 0.029* |